IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab

PURPOSE: Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metastatic colorectal cancer. Molecular predictors of B efficacy have still not been identified. We analyzed the role of 22 angiogenesis-associated proteins in patient outcome. PATIENTS AND METHODS: Serum...

Descripción completa

Detalles Bibliográficos
Autores principales: Marisi, Giorgia, Scarpi, Emanuela, Passardi, Alessandro, Nanni, Oriana, Pagan, Flavia, Valgiusti, Martina, Gardini, Andrea Casadei, Neri, Luca Maria, Frassineti, Giovanni Luca, Amadori, Dino, Ulivi, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241685/
https://www.ncbi.nlm.nih.gov/pubmed/30532588
http://dx.doi.org/10.2147/CMAR.S181570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241685/
https://www.ncbi.nlm.nih.gov/pubmed/30532588
http://dx.doi.org/10.2147/CMAR.S181570

Ejemplares similares